Mirum Pharmaceuticals/$MIRM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Ticker
$MIRM
Sector
Primary listing
Employees
349
Headquarters
Website
MIRM Metrics
BasicAdvanced
$3.8B
-
-$1.20
0.95
-
Price and volume
Market cap
$3.8B
Beta
0.95
52-week high
$78.54
52-week low
$36.88
Average daily volume
719K
Financial strength
Current ratio
3.131
Quick ratio
2.841
Long term debt to equity
124.165
Total debt to equity
124.981
Interest coverage (TTM)
-3.98%
Profitability
EBITDA (TTM)
-32.859
Gross margin (TTM)
79.02%
Net profit margin (TTM)
-13.65%
Operating margin (TTM)
-13.30%
Effective tax rate (TTM)
-2.10%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
-5.15%
Return on equity (TTM)
-24.19%
Valuation
Price to revenue (TTM)
8.635
Price to book
14.95
Price to tangible book (TTM)
220.61
Price to free cash flow (TTM)
-2,698.997
Free cash flow yield (TTM)
-0.04%
Free cash flow per share (TTM)
-0.028
Growth
Revenue change (TTM)
62.33%
Earnings per share change (TTM)
-49.89%
3-year revenue growth (CAGR)
123.36%
3-year earnings per share growth (CAGR)
-10.99%
What the Analysts think about MIRM
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
Bulls say / Bears say
In the second quarter of 2025, Mirum's total revenue jumped 64% year-over-year to reach $127.8 million, surpassing analyst expectations and prompting the company to increase its full-year 2025 revenue forecast to between $490 million and $510 million (Zacks)
Livmarli net product sales totaled $88.2 million in Q2 2025, representing an 87% year-over-year increase, fueled by robust demand in both the U.S. and international markets and highlighting Mirum’s leadership in cholestatic pruritus therapies (Zacks)
As of June 30, 2025, Mirum’s cash, cash equivalents, and investments increased to $321.7 million from $298.6 million as of March 31, strengthening its financial position as it continues to invest in research and development (Zacks)
Despite strong revenue growth, Mirum remained unprofitable in Q2 2025 with a loss per share of $0.12, signaling continued dependence on outside funding to support operations (Zacks)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
MIRM Financial Performance
Revenues and expenses
MIRM Earnings Performance
Company profitability
MIRM News
AllArticlesVideos
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire5 days ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mirum Pharmaceuticals stock?
Mirum Pharmaceuticals (MIRM) has a market cap of $3.8B as of October 16, 2025.
What is the P/E ratio for Mirum Pharmaceuticals stock?
The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of October 16, 2025.
Does Mirum Pharmaceuticals stock pay dividends?
No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Mirum Pharmaceuticals dividend payment date?
Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.
What is the beta indicator for Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.